Biotech Startups

Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms. The company serves patients with conditions including systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune disorders.

3 investors

Clinical-stage company developing topical therapies for rare skin diseases via its QTORIN platform.

3 investors

Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.

3 investors

Paradox Immuno develops a platform for discovering therapies targeting protein misfolding diseases, leveraging proprietary research and lead identification technology to address rare conditions with no existing treatments.

3 investors

Venture Capital portfolio company

3 investors

Parasma develops algorithms and infrastructure to train living neural systems for computation, aiming to make advanced AI far more energy-efficient and accessible by leveraging biological neurons as programmable compute. The company serves organizations seeking to reduce the energy footprint and hardware costs of AI systems.

3 investors

Paratus Sciences is a drug discovery company that uses AI-powered methods to identify first-in-class medicines by studying evolutionary traits, targeting serious diseases where current therapies are inadequate. The company combines computational discovery with drug development expertise to create new therapeutic programs.

3 investors

Passkey operates Locksmith, a computational platform that uses human genetics, biology, and pharmacology to identify synergistic drug combinations from approved and late-stage drugs, allowing existing assets to be repurposed for new indications. The company partners with pharmaceutical firms to map clinic-ready combinations that bypass preclinical development and move directly to human trials, initially targeting complex diseases such as cancer.

3 investors

Pathalys Pharma is a biotechnology company developing and improving therapeutic treatments for patients with chronic kidney disease.

3 investors

PathogenDx provides molecular pathogen detection assays using proprietary D3 Technology for rapid, multiplexed identification of bacterial, fungal, and viral pathogens in food, agricultural, clinical, and environmental samples.

3 investors

Pathotrak develops foodborne pathogen detection kits and a next-generation enrichment platform for food safety testing labs, offering fast time-to-results across sample types such as fresh produce, beef, poultry, and environmental swabs. Its products are designed to be USDA and FDA compliant.

3 investors

Pearl Diagnostics develops diagnostic assays for detecting fungal infections, including a urine-based test for Aspergillus. The company operates in the medical diagnostics and biotech industry.

3 investors

Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells. It targets conditions including androgenetic alopecia, drug-induced alopecia, and telogen effluvium, and is currently in clinical trials.

3 investors

PentaBind designs programmable aptamers—small RNA/DNA molecules with sub-nanomolar binding affinity—for continuous sensing and diagnostics applications (e.g., monitoring hormones and biomarkers) and targeted therapeutics in oncology and drug delivery. The platform reduces aptamer design cycles from months to ~22 days and delivers application-ready assets rather than just binders.

3 investors

PepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.

3 investors

Peptobiotics designs synthetic antimicrobial peptides intended to treat bacterial infections in farm animals. The peptides are made using cell-free production methods, which the company says avoids drug residues in animal products. The aim is to give livestock producers an alternative to conventional antibiotics and limit the spread of antimicrobial resistance.

3 investors

Peptomyc is a biotech company developing MYC inhibitors for cancer treatment, based on the Omomyc molecule, and is advancing them through preclinical and clinical trials. It operates in oncology drug development, with its research group linked to the Vall d'Hebron Institute of Oncology in Barcelona, Spain.

3 investors

Perfect Day produces ProFerm, an animal-free dairy protein made through fermentation, for use in sustainable dairy products. It aims to give food businesses a lower-impact supply chain while preserving the taste and properties of traditional dairy.

3 investors

Permanence Bio is a biotech company developing therapies aimed at cancer prevention by protecting the genome from damage, drawing on aging and DNA repair research. It works to discover cancer-preventing compounds and advance lead compounds from mechanism of action through IND-enabling studies and into the clinic.

3 investors

PetaGene develops PetaSuite, Linux software that losslessly compresses genomic data files (BAM and FASTQ.gz) by 60-90% while allowing tools to access files in their original format via on-the-fly decompression, both on-premises and in the cloud. It serves genomics research organizations, hospitals, and life sciences institutions to reduce storage costs and data transfer times.

3 investors

Petal is developing an incisionless surgery platform using Millisecond Pulse Histotripsy, a form of focused therapeutic ultrasound that breaks down targeted diseased tissue without incisions, heat, or trauma. The system is designed for patients, clinicians, and hospitals as an alternative to conventional and robotic surgery.

3 investors

PFx Biotech develops alternative protein products aimed at meeting high nutritional standards and offering health-promoting properties. The company operates in the alternative protein and biotech space.

3 investors

Pharmacelera develops computational chemistry software and services for drug discovery, using proprietary 3D molecular field descriptors, quantum mechanics, and AI to screen ultra-large chemical libraries and identify novel, synthesizable compounds. It serves small biotech companies, big pharma R&D departments, public research institutions, and CROs across stages from target identification to lead optimization.

3 investors

PharmaJet develops needle-free injection systems for delivering vaccines and therapeutics, used across a range of therapeutic areas including infectious disease prevention and cancer treatment. Its reusable devices serve pharmaceutical partners and healthcare providers as an alternative to traditional needle-based delivery.

3 investors